Andy Blake-Haskins

518 total citations
13 papers, 419 citations indexed

About

Andy Blake-Haskins is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Andy Blake-Haskins has authored 13 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Andy Blake-Haskins's work include Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (4 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Andy Blake-Haskins is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (4 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Andy Blake-Haskins collaborates with scholars based in United States, Italy and United Kingdom. Andy Blake-Haskins's co-authors include Jim Vasselli, Scott Antonia, Samir N. Khleif, Ramy Ibrahim, Jose Lutzky, Neil H. Segal, Paul B. Robbins, Julie R. Brahmer, Xia Li and Michele Maio and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Andy Blake-Haskins

13 papers receiving 407 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andy Blake-Haskins United States 8 379 201 126 63 30 13 419
Jim Vasselli United States 8 365 1.0× 205 1.0× 121 1.0× 47 0.7× 34 1.1× 10 406
Philip He United States 7 279 0.7× 84 0.4× 106 0.8× 72 1.1× 40 1.3× 22 459
Judith M. Versluis Netherlands 10 338 0.9× 158 0.8× 70 0.6× 68 1.1× 102 3.4× 43 408
Eriko Murakami Japan 6 409 1.1× 74 0.4× 194 1.5× 53 0.8× 57 1.9× 15 459
Mette Poehl Denmark 2 269 0.7× 145 0.7× 126 1.0× 31 0.5× 35 1.2× 7 318
Mélodie Tazdait France 4 229 0.6× 51 0.3× 138 1.1× 46 0.7× 15 0.5× 7 276
Grant Toland United States 3 310 0.8× 59 0.3× 194 1.5× 47 0.7× 22 0.7× 5 347
Bożena Cybulska-Stopa Poland 11 246 0.6× 81 0.4× 73 0.6× 22 0.3× 102 3.4× 58 330
Seung Tae Kim South Korea 9 186 0.5× 53 0.3× 169 1.3× 89 1.4× 67 2.2× 16 322
Erkki‐Ville Wirta Finland 10 303 0.8× 94 0.5× 87 0.7× 91 1.4× 51 1.7× 27 402

Countries citing papers authored by Andy Blake-Haskins

Since Specialization
Citations

This map shows the geographic impact of Andy Blake-Haskins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Blake-Haskins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Blake-Haskins more than expected).

Fields of papers citing papers by Andy Blake-Haskins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy Blake-Haskins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Blake-Haskins. The network helps show where Andy Blake-Haskins may publish in the future.

Co-authorship network of co-authors of Andy Blake-Haskins

This figure shows the co-authorship network connecting the top 25 collaborators of Andy Blake-Haskins. A scholar is included among the top collaborators of Andy Blake-Haskins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy Blake-Haskins. Andy Blake-Haskins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Powles, Thomas, Se Hoon Park, Éric Voog, et al.. (2022). Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.. Journal of Clinical Oncology. 40(6_suppl). 487–487. 20 indexed citations
2.
Pak, Min Gyoung, Carlos Chávez, Min Liang, et al.. (2015). 203 Population pharmacokinetics of MEDI4736, a fully human antiprogrammed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors. European Journal of Cancer. 51. S28–S28. 4 indexed citations
3.
Fairman, David, Rajesh Narwal, Meina Liang, et al.. (2014). Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2602–2602. 21 indexed citations
4.
Pinder, Mary, Naiyer A. Rizvi, Sarah B. Goldberg, et al.. (2014). A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in subjects with advanced non–small cell lung cancer.. Journal of Clinical Oncology. 32(15_suppl). e19137–e19137. 7 indexed citations
5.
Brahmer, Julie R., Naiyer A. Rizvi, Jose Lutzky, et al.. (2014). Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.. Journal of Clinical Oncology. 32(15_suppl). 8021–8021. 64 indexed citations
6.
Lutzky, Jose, Scott Antonia, Andy Blake-Haskins, et al.. (2014). A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 3001–3001. 85 indexed citations
7.
Segal, Neil H., Scott Antonia, Julie R. Brahmer, et al.. (2014). Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.. Journal of Clinical Oncology. 32(15_suppl). 3002–3002. 138 indexed citations
8.
Gordon, Michael S., Jose Lutzky, Donald P. Lawrence, et al.. (2014). Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma.. Journal of Clinical Oncology. 32(15_suppl). TPS9108–TPS9108. 3 indexed citations
9.
Segal, Neil H., Omid Hamid, Christophe Massard, et al.. (2014). A Phase I Multi-Arm Dose-Expansion Study of the Anti-Programmed Cell Death-Ligand-1 (Pd-L1) Antibody Medi4736: Preliminary Data. Annals of Oncology. 25. iv365–iv365. 40 indexed citations
10.
11.
Antonia, Scott, Sai‐Hong Ignatius Ou, Samir N. Khleif, et al.. (2014). Clinical Activity and Safety of Medi4736, an Anti-Programmed Cell Death-Ligand 1 (Pd-L1) Antibody, in Patients with Non-Small Cell Lung Cancer. Annals of Oncology. 25. iv466–iv466. 4 indexed citations
12.
Fury, Matthew G., Sai‐Hong Ignatius Ou, Ani Sarkis Balmanoukian, et al.. (2014). Clinical Activity and Safety of Medi4736, an Anti-Pd-L1 Antibody, in Patients with Head and Neck Cancer. Annals of Oncology. 25. iv341–iv341. 26 indexed citations
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jim Vasselli Breakdown of academic impact, for papers by Philip He Breakdown of academic impact, for papers by Judith M. Versluis Breakdown of academic impact, for papers by Eriko Murakami Breakdown of academic impact, for papers by Mette Poehl Breakdown of academic impact, for papers by Mélodie Tazdait Breakdown of academic impact, for papers by Grant Toland Breakdown of academic impact, for papers by Bożena Cybulska-Stopa Breakdown of academic impact, for papers by Seung Tae Kim Breakdown of academic impact, for papers by Erkki‐Ville Wirta
Rankless by CCL
2026